Search
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Hydrochlorothiazide
go.drugbank.com/drugs/DB00999ApprovedInvestigationalVet approved[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors.
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … [A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
Glecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalMavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].
Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L12660] This trial was later followed by phase II and III trials, where the Moderna COVID-19 Vaccine demonstrated vaccine efficacy of 94.1%. … Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by the novel coronavirus, SARS-CoV-2, leading to a respiratory illness alongside other complications.
Chymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnChymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637].
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedIt is currently marketed in Canada by Valeant under the tradename Cophylac.